ly3437943 retatrutide triple agonist glp-1 gip glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Structural insights into the triple

Those with a deficiency in vitamin 12 often have lower bone density, especially women, which can lead to weaker bones and osteoporosis

Currently enrolling clinical trials (T1-DISCO and Obesity Complicating T1D: GLP-1 Analogue Anti-Obesity Treatment) in young adults living with T1D and obesity are investigating the impacts of GLP-1s on cardiovascular outcomes

Methionine forms S-adenosyl-methionine (SAM) following activation by ATP, SAM serves as a key donor of methyl groups for cells and S-adenosyl-homocysteine (SAH) is formed when SAM is demethylated

Clin Genet 2017;92:188-98

Alle dosi consigliate non sono noti effetti collaterali rilevanti